A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Completed · Phase 1

Conditions studied: Chronic Spontaneous Urticaria

In brief

This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.

Key facts

Study ID

NCT04538794

Run by

Celldex Therapeutics

People needed

45

Starts

2020-09-24

Expected to finish

2023-01-17

Last updated by the study team

2023-07-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Research Center of Alabama — Birmingham, Alabama, United States
• Arizona Allergy & Immunology Research — Gilbert, Arizona, United States
• Sarasota Clinical Research — Sarasota, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Treasure Valley Medical Research — Boise, Idaho, United States
• Midwest Allergy, Sinus and Asthma, SC — Normal, Illinois, United States
• Dawes Fretzin Clinical Research — Indianapolis, Indiana, United States
• Kanarek Allergy Asthma & Immunology — Overland Park, Kansas, United States
• Bernstein Clinical Research Center, LLC — Cincinnati, Ohio, United States
• Vital Prospects Clinical Research Institute, PC — Tulsa, Oklahoma, United States
• Asthma, Nasal Disease & Allergy Research Center of New England — East Providence, Rhode Island, United States
• National Allergy and Asthma Research, LLC — North Charleston, South Carolina, United States
• AARA Research — Dallas, Texas, United States
• Charite University — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.